Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma - Evaluation of clinical benefit, quality of life, and tolerance

被引:56
作者
Gravis, G
Bladou, F
Salem, N
Macquart-Moulin, G
Serment, G
Camerlo, J
Genre, D
Bardou, VJ
Maraninchi, D
Viens, P
机构
[1] Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France
[2] Ctr Hosp Reg Univ Marseille, Hop Salvator, Dept Urol, Marseille, France
[3] INSERM, Unite 379, Res Unit, Marseille, France
[4] Univ Mediterranee, Dept Med, Marseille, France
[5] Inst Paoli Calmettes, Dept Biostat, Marseille, France
关键词
D O I
10.1002/cncr.11687
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The current Phase II study investigated the clinical benefit, impact on quality of life (QOL), and tolerability of weekly docetaxel in symptomatic patients with metastatic hormone-refractory prostate carcinoma (HRPC). METHODS. Patients received weekly docetaxel 35 mg/m(2) intravenously for 6 consecutive weeks followed by a 2-week rest repeatedly for a maximum of 24 weeks of treatment. Clinical benefit evaluations, based on Karnofsky performance status (KPS) and pain, were assessed weekly during therapy. A clinical benefit response was defined as a sustained (greater than or equal to 4-week) improvement in at least one of these parameters without worsening in the other. Patient-assessed QOL (using the European Organization for Research and Treatment of Cancer QLQ-C30), changes in prostate-specific antigen (PSA) levels, tumoral response, and toxicity also were evaluated. RESULTS. Thirty men (median age, 67 years), 15 of whom had received previous chemotherapy, were treated. Overall, 46% of patients achieved a positive pain response and 48% achieved a 50%-or-greater reduction in PSA. KPS was high at baseline (80%), and no significant changes in this parameter were observed. Compared with baseline, all scores improved after the first cycle of therapy, particularly emotional (P = 0.015), pain (P = 0.001), constipation (P = 0.001), and global QOL (P = 0.011) scores. After the second cycle, dyspnea scores decreased (P = 0.010). At the last QOL assessment, there also was deterioration in terms of fatigue (P = 0.013), dyspnea (P = 0.010), and physical functioning (P = 0.017). Toxicity was mild and included neutropenia (Grade 3-4, n = 2). CONCLUSIONS. Of these elderly symptomatic patients with HRPC, half had received previous chemotherapy. Weekly docetaxel was found to be associated with improvements in clinical benefit response and in QOL and was well tolerated. (C) 2003 American Cancer Society.
引用
收藏
页码:1627 / 1634
页数:8
相关论文
共 23 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]  
*AM CANC SOC, 2001, CANC FACTS FIG 2001, P16
[3]   Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer [J].
Beer, TM ;
Pierce, WC ;
Lowe, BA ;
Henner, WD .
ANNALS OF ONCOLOGY, 2001, 12 (09) :1273-1279
[4]   Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group [J].
Bubley, GJ ;
Carducci, M ;
Dahut, W ;
Dawson, N ;
Daliani, D ;
Eisenberger, M ;
Figg, WD ;
Freidlin, B ;
Halabi, S ;
Hudes, G ;
Hussain, M ;
Kaplan, R ;
Myers, C ;
Oh, W ;
Petrylak, DP ;
Reed, E ;
Roth, B ;
Sartor, O ;
Scher, H ;
Simons, J ;
Sinibaldi, V ;
Small, EJ ;
Smith, MR ;
Trump, DL ;
Vollmer, R ;
Wilding, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3461-3467
[5]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[6]   A CONTROLLED TRIAL OF LEUPROLIDE WITH AND WITHOUT FLUTAMIDE IN PROSTATIC-CARCINOMA [J].
CRAWFORD, ED ;
EISENBERGER, MA ;
MCLEOD, DG ;
SPAULDING, JT ;
BENSON, R ;
DORR, FA ;
BLUMENSTEIN, BA ;
DAVIS, MA ;
GOODMAN, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (07) :419-424
[7]   The quality of life of patients with newly diagnosed M1 prostate cancer: Experience with EORTC clinical trial 30853 [J].
daSilva, FC ;
Fossa, SD ;
Aaronson, NK ;
Serbouti, S ;
Denis, L ;
Casselman, J ;
Whelan, P ;
Hetherington, J ;
Fava, C ;
Richards, B ;
Robinson, MRG .
EUROPEAN JOURNAL OF CANCER, 1996, 32A (01) :72-77
[8]  
FAYERS P, 1999, QLQC30 EORTC
[9]   Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer [J].
Fennelly, D ;
Aghajanian, C ;
Shapiro, F ;
OFlaherty, C ;
McKenzie, M ;
OConnor, C ;
Tong, W ;
Norton, L ;
Spriggs, D .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :187-192
[10]   Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trial [J].
Fields-Jones, S ;
Koletsky, A ;
Wilding, G ;
O'Rourke, M ;
O'Rourke, T ;
Eckardt, J ;
Yates, B ;
McGuirt, C ;
Burris, HA .
ANNALS OF ONCOLOGY, 1999, 10 (11) :1307-1310